The nurse assisting with Phase 1 drug studies is talking with a woman who asks, "Why can't I participate in this study?" What would be the nurse's best response?

Choice A rationale

Working with animals is typically done in preclinical trials before phase I studies in humans and is not part of phase III drug evaluation studies.

Choice B rationale

Conducting research to determine the effectiveness of the drug is part of phase II studies. Phase III studies focus more on confirming effectiveness, monitoring side effects, and comparing it to commonly used treatments.

Choice C rationale

Monitoring and observing patients closely for adverse effects is a key responsibility in phase III drug evaluation studies. These studies involve a larger patient population to gather comprehensive safety and efficacy data.

Choice D rationale

Choosing appropriate patients to be involved in the study is primarily the responsibility of researchers and clinicians during the earlier phases of drug development, such as phase I and phase II studies.

Choice A rationale

Plaque formation in arteries does not start with platelets and fibrin.

Choice B rationale

Plaque begins with fatty streaks, which are the earliest signs of atherosclerosis and consist of lipid-laden cells in the arterial wall.

Choice C rationale

White blood cells are involved in the inflammatory process of atherosclerosis but do not represent the initial plaque formation.

Choice D rationale

Foam cells, which are lipid-laden macrophages, develop later in the process of plaque formation and contribute to the growth of atherosclerotic lesions. .